PULSE the living trend engine
🤖 Open Intelligence Dossier available for AI agents & citation View Markdown (.md) →
◼ Archived Business 🔮 PULSE predicts: fades by tomorrow

Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles

Vertex Pharma's $10 billion purchase of Crinetics sparks a near‑doubling of its shares and a biotech‑M&A surge

7sources
9articles
6velocity
+0%since first seen
108d agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

Vertex Pharma agreed to acquire Crinetics Pharmaceuticals for $10 billion, a deal highlighted across multiple business outlets. Coverage from Yahoo Finance, Barron's, The Boston Globe and others emphasizes the stock reaction—CRNX shares doubled, reached 52‑week highs, and a reported 99% surge.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (50% supported) Updated 105d ago.

Quick answers

What is the financial size of the Vertex‑Crinetics transaction?

The deal is valued at $10 billion.

How did Crinetics’ stock respond to the announcement?

Crinetics shares doubled, hit 52‑week highs and were reported to have risen 99%.

Which therapeutic areas does the acquisition target?

Coverage cites a strengthening of Vertex’s rare‑disease portfolio and entry into endocrine disease drugs.

Coverage (9)

Topics

Vertex Pharma Crinetics Pharmaceuticals biotech M&A rare disease endocrine drugs

Related trends

◼ Archived Business

Shionogi to Acquire IntraBio for $2 Billion

Japanese pharmaceutical company Shionogi has agreed to acquire Texas-based rare disease biotech IntraBio in a deal valued at $2 billion.

9 sources 10 articles v 8 17d ago
\n \n \n \n \n \n \n